These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30391422)

  • 1. Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy.
    Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
    Peptides; 2018 Dec; 110():19-29. PubMed ID: 30391422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonists.
    Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
    Mol Cell Endocrinol; 2019 Jan; 480():54-64. PubMed ID: 30312651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
    Conlon JM; O'Harte FPM; Flatt PR
    Peptides; 2022 Jan; 147():170706. PubMed ID: 34861327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities.
    Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
    Eur J Pharmacol; 2020 Jul; 878():173101. PubMed ID: 32320703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
    Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
    Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
    O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
    Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A long-acting, dual-agonist analogue of lamprey GLP-1 shows potent insulinotropic, β-cell protective, and anorexic activities and improves glucose homeostasis in high fat-fed mice.
    Graham GV; McCloskey A; Abdel-Wahab YH; Conlon JM; Flatt PR
    Mol Cell Endocrinol; 2020 Jan; 499():110584. PubMed ID: 31539596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39).
    Fehmann HC; Jiang J; Schweinfurth J; Wheeler MB; Boyd AE; Göke B
    Peptides; 1994; 15(3):453-6. PubMed ID: 7937318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
    Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
    Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.
    ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Naing SW; Kuwayama H
    Domest Anim Endocrinol; 2017 Apr; 59():30-36. PubMed ID: 27888738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
    Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
    Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.
    Ali S; Lamont BJ; Charron MJ; Drucker DJ
    J Clin Invest; 2011 May; 121(5):1917-29. PubMed ID: 21540554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle.
    ThanThan S; Saito T; Yannaing S; Zhao H; Nakashima K; Kuwayama H
    Domest Anim Endocrinol; 2012 Apr; 42(3):155-64. PubMed ID: 22154917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.
    Willard FS; Wootten D; Showalter AD; Savage EE; Ficorilli J; Farb TB; Bokvist K; Alsina-Fernandez J; Furness SG; Christopoulos A; Sexton PM; Sloop KW
    Mol Pharmacol; 2012 Dec; 82(6):1066-73. PubMed ID: 22930710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
    Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
    Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL; Huang Q; Brown TJ; Drucker DJ
    Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
    Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
    Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.